Особенности реализации репродуктивной функции у женщин с ВИЧ-инфекцией

1. Информационный бюллетень ВОЗ № 360 от июля 2016 г.

2. Ладная Н. Разработка целей всеобщего (универсального) доступа к профилактике, лечению, уходу и поддержке в связи с ВИЧ/СПИД. Федеральный центр СПИД; 2016.

3. Márquez M., Romero-Cores P., Montes-Oca M., Martín-Aspas A., Soto-Cárdenas M.J., Guerrero F. et al. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection. PLoS One. 2015;10(3): e0119568.

4. Elford J., Ibrahim F., Bukutu C., Anderson J. Sexual behaviour of people living with HIV in London: implications for HIV transmission. AIDS. 2007; 21(Suppl. 1): S63-70.

5. AIDS Global Report. 2010. Available at: http://www.unaids.org/globalreport/Global_report.htm

6. Simon V., Ho D.D., Abdool Karim Q. HIV/AIDS epidemiology, athogenesis, prevention, and treatment. Lancet. 2006; 368(9534): 489-504.

7. ACOG Committee on Practice Bulletins-Gynecology. Gynecologic care for women with human immunodeficiency virus. Practice Bulletin No. 117. Obstet. Gynecol. 2010; 116(6): 1492-509.

8. Kovacs A., Wasserman S.S., Burns D., Wright D.J., Cohn J., Landay A. et al. Determinations of HIV-1 shedding in the genital tract of women. Lancet. 2001; 358(9293): 1593-601.

9. Самарина А.В. Стратегия ограничения распостранения ВИЧ-инфекции у женщин репродуктивного возраста и риска перинатального заражения: автореф. дисс. … д-ра мед. наук. СПб.; 2014.

10. Zaba B., Terceira N., Mason P., Gregson S. The contribution of HIV to fertility decline in rural Zimbabwe, 1985-2000. Popul. Stud. (Camb.) 2003; 57(2): 149-64.

11. Massad L.S., Springer G., Jacobson L., Watts H., Anastos K., Korn A. et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004; 18(2): 281-6.

12. Покровская А.В., Козырина Н.В., Гущина Ю.Ш., Юрин О.Г., Суворова З.К., Покровский В.В.; рабочая группа «Портрет пациента». Социально-демографический портрет пациента, живущего с ВИЧ, посещающего центры СПИД в России. Терапевтический архив. 2016; 88(11): 12-6. doi: 10.17116/terarkh2016881112-16.

13. Parson T., Brigham K. Fertility rate of HIV-infected women is 37 percent less than that of healthy women. Johns Hopkins Bloomberg School of Public Health. May 15, 2000.

14. Shannon J., Benrubi G.I. Epidemiology of pelvic inflammatory disease at University Medical Centre, Jacksonville. J. Fla Med. Assoc. 1991; 78(3): 158-61.

15. Coll O., Lopez M., Hernandez S. Fertility choices and management for HIV-positive women. Curr. Opin. HIV AIDS. 2008; 3(2): 186-92.

16. Cohen C.R., Sinei S., Reilly M., Bukusi E., Eschenbach D., Holmes K.K. et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J. Infect. Dis. 1998; 178(5): 1352-8.

17. Ellis M., Gupta S., Galant S., Hakim S., VandeVen C., Toy C. et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J. Infect. Dis. 1988; 158(6): 1268-76.

18. Watts D.H., Springer G., Minkoff H., Hillier S.L., Jacobson L., Moxley M. et al. Occurrence of vaginal infections among HIV-Infected and high-risk HIV- uninfected women: longitudinal findings of the Women’s Interagency HIV Study. J. Acquir. Immune Defic. Syndr. 2006; 43(2): 161-8.

19. Ahdieh L., Klein R.S., Burk R., Cu-Uvin S., Schuman P., Duerr A. et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HlV)-positive and HIV-negative women. J. Infect. Dis. 2001; 184(6): 682-90.

20. Jamieson D.J., Duerr A., Burk R. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am. J. Obstet. Gynecol. 2002; 186: 21-7.

21. McKenzie N.D., Kobetz E.N., Hnatyszyn J., Twiggs L.B., Lucci J.A. 3rd. Women with HIV are more commonly infected with non-16 and -18 high-risk HpV types. Gynecol. Oncol. 2010; 116(3): 572.

22. Mbulaiteye S.M., Biggar R.J., Goedert J.J., Engels E.A. Immune deficiency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defic. Syndr. 2003; 32(5): 527-33.

23. Massad L.S., Seaberg E.C., Watts D.H., Hessol N.A., Melnick S., Bitterman P. et al. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS. 2004; 18(1): 109-13.

24. Clifford G.M., Polesel J., Rickenbach M., Dal Maso L., Keiser O., Kofler A. et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl. Cancer Inst. 2005; 97(6): 425-32.

25. Chirgwin K.D., Feldman J., Muneyyirci-Delale O., Landesman S., Minkoff H. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996; 12(5): 489-94.

26. Cejtin H.E., Kalinowski A., Bacchetti P., Taylor R.N., Watts D.H., Kim S. et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet. Gynecol. 2006; 108(6): 1423-31.

27. Schoenbaum E.E., Hartel D., Lo Y., Howard A.A., Floris-Moore M., Arnsten J.H., Santoro N. HIV infection, drug use, and onset of natural menopause. Clin. Infect. Dis. 2005; 41(10): 1517-24.

28. Seifer D.B., Golub E.T., Lambert-Messerlian G., Springer G., Holman S., Moxley M. et al. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertil. Steril. 2007; 88(6): 1645-52.

29. Ohl J., Partisani M., Demangeat C., Binder-Foucard F., Nisand I., Lang J.M. Alterations of ovarian reserve tests in human immunodeficiency virus (HIV)-infected women. Gynecol. Obstet. Fertil. 2010; 38(5): 313-7.

30. Baccetti B., Benedetto A., Collodel G., Di Caro A., Garbuglia A.R., Piomboni P. The debate on the presence of HIV-1 in human gametes. J. Reprod. Immunol. 1998; 41: 41-67.

31. Englert Y., Lesage B., Van Vooren J.P., Liesnard C., Place I., Vannin A.S. et al. Medically assisted reproduction in the presence of chronic viral diseases. Hum. Reprod. Update. 2004; 10(2): 149-62.

32. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999; 354(9184): 1112-5.

33. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 2000; 22(6):685-708.

34. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2003;2(10): 812-22.

35. Венхофф Н., Уокер У.А. Токсическое действие НИОТ на митохондрии. В кн.: Хоффман К., Рокштро Ю.К., ред. Лечение ВИЧ-инфекции 2011. Пер. с англ. М.: Р.Валент; 2012: 315-320.

36. Gingelmaier A., Grubert T.A., Kost B.P., Setzer B., Lebrecht D., Mylonas I. et al. Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy. Antivir. Ther. 2009; 14(3): 331-8.

37. Reynier P., May-Panloup P., Chrétien M.F., Morgan C.J., Jean M., Savagner F. et al. Mitochondrial DNA content affects the fertilizability of human oocytes. Mol. Hum. Reprod. 2001; 7(5): 425-9.

38. López S., Coll O., Durban M., Hernàndez S., Vidal R., Suy A. et al. Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile women Antivir. Ther. 2008; 13(6): 833-8.

39. Bostan A., Demeestere I., Vanderwinden J.M., Devreker F., Englert Y. Nucleoside analog stavudine depletes mitochondrial DNA with no organelle loss in mouse oocytes. Curr. HIV Res. 2010; 8(2): 127-33.

40. Van Leeuven E., Prins J.M., Jurriaans S., Boer K., Reiss P., Repping S. Reproduction and fertility in human immunodeficiency virus type-1 infection. Hum. Reprod. Update. 2007; 13(2): 197-206.

41. Кузьмин В.Н., Машина М.А. ВИЧ-инфекция и экстракорпоральное оплодотворение: проблема и пути решения. Лечащий врач. 2015; 1: 87-91.

42. Sauer M.V., Wang J.G., Douglas N.C., Nakhuda G.S., Vardhana P., Jovanovic V., Guarnaccia M.M. Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection. Fertil. Steril. 2009; 91(6): 2455-60.

43. Savasi V., Ferrazzi E., Lanzani C., Oneta M., Parrilla B., Persico T. Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples. Hum. Reprod. 2007; 22(3): 772-7.

44. Приказ Министерства здравоохранения РФ № 107н от 30 августа 2012 г. „О порядке использования вспомогательных репродуктивных технологий, противопоказаниях и ограничениях к их применению”.

45. Bagratee J.S. HIV/AIDS and reproduction: Background and indication for treatment. In: Kruger T.F., Van der Spuy Z., Kempers R.D., eds. Advances in Fertility Studies and Reproductive Medicine. Cape Town, Juta; 2007:414-9.

46. Frodsham L., Cox A.D., Almeida A., Rozis G., Gilling-Smith C. In vitro fertilization in HIV positive women: potential mother and embryo viral transmission risk. Hum. Reprod. 2004; 19(Suppl. 1): abstr.103.

47. Ohl J., Partisani M., Wittemer C., Schmitt M.P., Cranz C., Stoll- Keller F. et al. Assisted reproduction techniques for HIV serodiscordant couples: 18 month experience. Hum. Reprod. 2003; 18(6): 1243-9.

48. Краснопольская К.В., Назаренко Т.А., Гафуров Ю.Т. Место вспомогательных репродуктивных технологий в реализации репродуктивной функции у ВИЧ-инфицированных лиц. Российский вестник акушера-гинеколога. 2013; 13(3): 47-55.

49. Stora C., Epelboin S., Devouche E., Matheron S., Epelboin L., Yazbeck C. et al. Women infected with human immunodeficiency virus type 1 have poorer assisted reproduction outcomes: a case-control study. Fertil. Steril. 2016; 105(5): 1193-2011.

50. Martinet V., Manigart Y., Rozenberg S., Becker B., Gerard M., Delvigne A. Ovarian response to stimulation of HIV-positive patients during IVF treatment: a matched, controlled study. Hum. Reprod. 2006; 21(5): 1212-7.

51. Coll O., Suy A., Figueras F., Vernaeve V., Martı´nez E., Mataro´ D. et al. Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART. AIDS. 2006; 20(1): 121-3.

52. Адамян Л.В., Афонина Л.Ю., Баранов И.И., Воронин Е.Е., Кан Н.Е., Кузьмин В.Н., Козырина Н.В., Покровский В.В., Садовникова В.Н., Юрин О.Г., Фомин Ю.А. Применение антиретровирусных препаратов в комплексе мер, направленных на профилактику передачи ВИЧ от матери ребенку. Клинические рекомендации (протокол лечения). М.; 2015.

53. Baroncelli S., Tamburrini E., Ravizza M., Pinnetti C., Dalzero S., Scata' M. et al. Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Pregnancy outcomes in women with advanced HIV infection in Italy. AIDS Patient Care STDS. 2011; 25(11): 639-45.

54. Mohamed M., Vismas A., Sabatini L., Caragia A., Collins B., Leach A. et al. Women with HIV have lower fertility potential: a case control study. Hum. Reprod. 2012; 27: ii226-47.

55. Thorne C., Patel D., Newell M.L. Increased risk of adverse pregnancy otcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004; 18(17): 2337-9.

Поступила 25.05.2017

Принята в печать 23.06.2017